This Fidelity fund is way in the money on sale of pharma firm

This Fidelity fund is way in the money on sale of pharma firm
A Fidelity equity fund stands to reap $478.4 million on its stake in a pharmaceutical firm
MAR 12, 2012
Steven Wymer's Fidelity Growth Company Fund stands to reap $478.4 million on its stake in Pharmasset Inc. after Gilead Sciences Inc. agreed to buy the drug company at an 89 percent premium. The $38.5 billion Fidelity Growth fund held 7.44 million shares of Pharmasset as of Sept. 30, a stake valued at about $540.4 million at the end of last week, according to data compiled by Bloomberg. Gilead today offered to pay $137 a share in cash for Pharmasset, which would boost the value of Fidelity's holding to $1.02 billion. Wymer, who has managed the Fidelity Growth fund since 1997, invests in companies that he believes have above-average growth potential. He started amassing a stake in Pharmasset in the second quarter of 2008 and over the next three years almost tripled his holding in the drug company, according to data compiled by Bloomberg. About 16 percent of the fund is invested in health-care companies, according to information posted on Fidelity's website. “By far, the biggest contributor to the fund's relative performance was strong stock picking in health care, specifically in the pharmaceuticals / biotechnology and life science area,” Wymer wrote in a May 31 report to shareholders. Princeton, New Jersey-based Pharmasset, which is developing experimental hepatitis C treatments, was the seventh-largest holding in the Fidelity Growth fund as of Sept. 30, according to data compiled by Bloomberg. The top holding in the fund is Apple Inc., whose shares have advanced 13.6 percent this year. Beating Rivals The fund declined 1 percent this year through Nov. 18, doing better than 79 percent of similarly managed funds. It advanced at an average annual rate of 3.6 percent over the past five years, beating 84 percent of peers. Sophie Launay, a spokeswoman for Boston-based Fidelity, declined to comment on the stake. Fidelity, which has also invested in Pharmasset through other mutual funds, is the biggest shareholder in the company, owning 12.7 percent of the outstanding shares in Pharmasset. Another mutual funds which stands to gain from Pharmasset is the $7.8 billion T. Rowe Price New Horizons Fund. The fund owns about 1.64 million shares of the company, according to data compiled by Bloomberg. --Bloomberg News--

Latest News

SEC Says Game Service Roblox Part of ‘Active Investigation’
SEC Says Game Service Roblox Part of ‘Active Investigation’

Short sellers previously said the company was under investigation, though Roblox denied allegations.

Musk’s DOGE descends on CFPB with intention to shut it down
Musk’s DOGE descends on CFPB with intention to shut it down

The Consumer Financial Protection Bureau is in the crosshairs of the Republican group that is widely attempting to dismantle government agencies.

Advisor fighting Finra banishment loses $17.7 million dispute with old firm
Advisor fighting Finra banishment loses $17.7 million dispute with old firm

National Securities Corp. sued the advisor in 2020, alleging breach of contract and unjust enrichment.

Job numbers, inflation leaving room for Fed to hold rates
Job numbers, inflation leaving room for Fed to hold rates

Recent data support a measured pace by the Federal Reserve for the year ahead.

Private assets remain hot despite surging stock market
Private assets remain hot despite surging stock market

Financial advisors are still adding alternatives despite the surge in publicly traded stock prices

SPONSORED Taylor Matthews on what's behind Farther's rapid growth

From 'no clients' to reshaping wealth management, Farther blends tech and trust to deliver family-office experience at scale.

SPONSORED Why wealth advisors should care about the future of federal tax policy

Blue Vault features expert strategies to harness for maximum client advantage.